2017 PROGRAMME


REGISTER NOW


HOTEL BOOKING FORM


ADVERTISING, EXHIBITION & SPONSORSHIP OPPORTUNITIES

REGISTER FOR BOTH THE 10th PHARMACOVIGILANCE CONFERENCE AND
THE 16th REGULATORY AND SCIENTIFIC AFFAIRS CONFERENCE AND GET A 10% DISCOUNT!

videophvThe Pharmacovigilance conference, organised yearly by Medicines for Europe, is a unique event where key stakeholders gather with the aim of promoting patient safety and undertaking to continue work towards a more efficient pharmacovigilance system. In the spirit of constructive cooperation, this event brings together representatives from the industry and regulators as well as healthcare professionals and patient organisations.

Morning sessions reflect on achievements so far and focus on the milestones ahead. An open dialogue between key stakeholders has proven to be the right approach for making significant progress towards better pharmacovigilance for better public protection.

Traditional afternoon brainstorming sessions stimulate a lively, engaging debate incorporating all perspectives. Hot topics are debated to identify the best possible processes and tools leading to better access to high quality medicines in Europe.Register now for the 10th Medicines for Europe Pharmacovigilance Conference.

In 2016 a record number of participants attended and more than 20 competent authorities were present, so DO NOT MISS the 2017 edition!

Find out more Medicines for Europe events here.

twitter-128#PHV17

20160128 EGA Regulatory and Scientific Affairs Conference

Topics

Session 1: Pharmacovigilance legislation: what are the next steps? Reflections from the Commission, European Medicines Agency and the Industry.

  • The 3-year Commission report and Impact assessment, led by the EMA
  • Scanning the horizon: what are the milestones ahead of us?
  • Social media and technology supporting patient safety: opportunities and pitfalls

Session 2: Enhanced EudraVigilance & Signal Detection – how to prepare for the upcoming milestones? Reflections of the regulators and the industry perspective.

  • EudraVigilance stakeholder change management
  • How can companies ensure smooth implementation? – case study
  • Overview of the new process for Signal Detection and Management

Session 3: Mini Workshops: how to improve pharmacovigilance activities?

  • Educational material – is there a more efficient way to educate?
  • Medical literature monitoring – service improvements after one year implementation
  • Pharmacovigilance inspections and compliance – is there a more efficient way when companies are auditing each other?
  • Signal detection – what and how to implement the changes?
  • Pharmacovigilance of Biologicals – implementation of GVP P.II recommendations

All sessions will be followed by a panel discussion and interaction with the floor.

PROGRAMME 2017 NOW AVAILABLE

CHAIRPERSONS AND SPEAKERS

 

Paul Scannell
Chair of the Medical Devices Task Force Medicines for Europe and Mylan
Paul ScannellChair of the Medical Devices Task Force Medicines for Europe and Mylan
June Raine, Dr.
PRAC Chair, Director of Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency (MHRA), UK
June Raine, Dr.PRAC Chair, Director of Vigilance and Risk Management of Medicines, Medicines and Healthcare products Regulatory Agency (MHRA), UK
Phil Tregunno
Signal Management & Quality Standards Unit Manager, Medicines & Healthcare products Regulatory Agency (MHRA)
Phil TregunnoSignal Management & Quality Standards Unit Manager, Medicines & Healthcare products Regulatory Agency (MHRA)
Jamie Wilkinson, MSc, PGCert, MPharm (Hons), Dip HE, FRSPH
MRPharmS, Director of Professional Affairs, Pharmaceutical Group of the European Union (PGEU)
Jamie Wilkinson, MSc, PGCert, MPharm (Hons), Dip HE, FRSPHMRPharmS, Director of Professional Affairs, Pharmaceutical Group of the European Union (PGEU)
John Barber
QPPV and Director, Head of Pharmacovigilance, European Operations, Dr. Reddy’s
John BarberQPPV and Director, Head of Pharmacovigilance, European Operations, Dr. Reddy’s
Julia Appelskog
QPPV and Head of Pharmacovigilance, Bluefish Pharmaceuticals
Julia AppelskogQPPV and Head of Pharmacovigilance, Bluefish Pharmaceuticals
Nicole Lang
Senior Director, PhV TA Group Leader, Biologics, Respiratory & IM, Global Patient Safety & Pharmacovigilance, TEVA
Nicole LangSenior Director, PhV TA Group Leader, Biologics, Respiratory & IM, Global Patient Safety & Pharmacovigilance, TEVA
Michael Forstner
Managing Director and Head Pharmacovigilance/ Pharmacoepidemiology Practice, Mesama Consulting Switzerland
Michael ForstnerManaging Director and Head Pharmacovigilance/ Pharmacoepidemiology Practice, Mesama Consulting Switzerland
Barbara Claus
Hospital Pharmacist, Ghent University Hospital
Barbara ClausHospital Pharmacist, Ghent University Hospital

SPONSORS AND MEDIA PARTNERS

logo-gabi  

CONTACT

Lucia Romagnoli
M: +44 (0) 7 562 87 68 73